---
title: "759CVR012TMP.US (759CVR012TMP.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/759CVR012TMP.US/news.md"
symbol: "759CVR012TMP.US"
name: "759CVR012TMP.US"
parent: "https://longbridge.com/en/quote/759CVR012TMP.US.md"
datetime: "2026-03-10T02:18:04.819Z"
locales:
  - [en](https://longbridge.com/en/quote/759CVR012TMP.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/759CVR012TMP.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/759CVR012TMP.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/759CVR012TMP.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/759CVR012TMP.US/news.md)


# 759CVR012TMP.US (759CVR012TMP.US) — Related News

### [iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s](https://longbridge.com/en/news/273064683.md)
*2026-01-20T09:25:48.000Z*
> iRegene Therapeutics has received RMAT designation from the US FDA for its lead product, NouvNeu001, aimed at treating P